StockData
Arbutus Biopharma Corp logo

Arbutus Biopharma Corp (ABUS) income statement

ABUSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 14/3073% below fair value
$4.05+0.01 (+0.25%)

Close on Nov 17, 2026Market cap $801.28MP/E 5.2Yield –

Arbutus Biopharma Corp income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
–
Operating margin
82.0%
Net margin
84.2%
Return on equity, FY2025
-38.5%

Financial strength

Current ratio
81.42
Debt to equity
–
Debt to assets
–
Cash to current liabilities
569.9%

Valuation

P/E ratio
5.2
Price to sales
4.41
Price to book
3.10
Dividend yield
–

See a number that looks wrong?